David A. Siegel Hepion Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.27 - $11.9 $1,134 - $49,980	-4,200 Reduced 13.95%	25,900 $7,000
Q3 2022 Nov 14, 2022	SELL	$0.51 - $10.4 $8,007 - $163,280	-15,700 Reduced 34.28%	30,100 $15,000
Q2 2022 Aug 15, 2022	SELL	$0.57 - $1.22 $20,577 - $44,042	-36,100 Reduced 44.08%	45,800 $26,000
Q1 2022 May 16, 2022	SELL	$0.93 - $1.29 $22,878 - $31,734	-24,600 Reduced 23.1%	81,900 $106,000
Q4 2021 Feb 14, 2022	SELL	$1.14 - $1.58 $18,810 - $26,070	-16,500 Reduced 13.41%	106,500 $121,000
Q3 2021 Nov 15, 2021	SELL	$1.39 - $2.1 $1.04 Million - $1.57 Million	-748,200 Reduced 85.88%	123,000 $188,000
Q2 2021 Aug 16, 2021	BUY	$1.56 - $2.26 $1.17 Million - $1.69 Million	747,900 Added 606.57%	871,200 $1.73 Million
Q1 2021 May 17, 2021	BUY	$1.77 - $2.98 $218,241 - $367,434	123,300 New	123,300 $227,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $51.8M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.